Medical Need today announced that it has entered into an exclusive licensing and supply agreement with US based Tactic Pharma, relating to their product Decuprate™ (choline tetrathiomolybdate), also known as ATN-224. The product is a small, orally available molecule, acting as a highly potent and specific copper binder. Decuprate™ is under development for the treatment of Wilson’s disease in both the acute and maintenance setting. Under the agreement, Medical Need holds the exclusive rights to Decuprate™ in Europe, including all EU member states, Norway, Iceland, Switzerland, Turkey and the Balkans, and will be responsible for the registration, distribution, marketing and sale of the product in the territory. Initially, the product will on request be provided on a named patient basis.
About Wilson’s disease
Wilson’s disease is a rare inherited condition caused by malfunction in an enzyme central to the body’s copper metabolism, leading to a decreased ability to process, bind and excrete copper. Consequently, copper is accumulated over time, leading to severe symptoms typically presenting acutely in early adulthood. Symptoms include liver failure, neurological damage and other severely debilitating consequences. Left untreated, the disease is fatal. Wilson’s disease exists in all ethnicities and it is estimated that the condition affects on average 1 in every 30-50 thousand new borns.
About Tactic Pharma
Tactic Pharma is a biopharmaceutical company developing pre-clinical and clinical stage compounds for unmet medical needs. Tactic currently has four compounds under development within rare disorders and oncology. More information on Tactic can be found on www.tacticpharma.com
About Medical Need
Medical Need is a Sweden based pharmaceutical company, focusing on the registration, distribution, marketing and sale of orphan drugs and niche specialty pharmaceuticals for unmet medical needs in Europe. More information on Medical Need can be found on www.medicalneed.com